Acelyrin, Inc. (NASDAQ:SLRN) Shares Acquired by OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Acelyrin, Inc. (NASDAQ:SLRN) by 29.4% during the fourth quarter, Holdings Channel reports. The institutional investor owned 211,938 shares of the company’s stock after purchasing an additional 48,214 shares during the quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Acelyrin were worth $665,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Barclays PLC boosted its position in shares of Acelyrin by 208.8% during the 3rd quarter. Barclays PLC now owns 96,408 shares of the company’s stock worth $475,000 after purchasing an additional 65,188 shares in the last quarter. Franklin Resources Inc. lifted its stake in shares of Acelyrin by 36.9% in the third quarter. Franklin Resources Inc. now owns 128,591 shares of the company’s stock valued at $634,000 after purchasing an additional 34,642 shares during the period. Intech Investment Management LLC boosted its holdings in Acelyrin by 71.0% during the fourth quarter. Intech Investment Management LLC now owns 26,587 shares of the company’s stock worth $83,000 after buying an additional 11,040 shares in the last quarter. American Century Companies Inc. boosted its holdings in Acelyrin by 146.0% during the fourth quarter. American Century Companies Inc. now owns 78,868 shares of the company’s stock worth $248,000 after buying an additional 46,802 shares in the last quarter. Finally, Wellington Management Group LLP acquired a new position in Acelyrin during the fourth quarter worth about $567,000. Institutional investors and hedge funds own 87.31% of the company’s stock.

Acelyrin Trading Down 15.7%

Shares of Acelyrin stock opened at $2.09 on Wednesday. The company has a 50-day moving average of $2.44 and a two-hundred day moving average of $3.06. Acelyrin, Inc. has a 12-month low of $1.85 and a 12-month high of $7.25. The stock has a market cap of $210.90 million, a PE ratio of -0.85 and a beta of 1.07.

Acelyrin (NASDAQ:SLRN) last released its quarterly earnings results on Wednesday, March 19th. The company reported ($0.79) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.07. On average, sell-side analysts forecast that Acelyrin, Inc. will post -2.53 EPS for the current fiscal year.

Insiders Place Their Bets

In other Acelyrin news, CEO Mina Kim sold 17,986 shares of Acelyrin stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $2.74, for a total transaction of $49,281.64. Following the completion of the transaction, the chief executive officer now owns 671,753 shares in the company, valued at approximately $1,840,603.22. The trade was a 2.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 13.60% of the stock is owned by company insiders.

Acelyrin Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.